Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.37 |
| ▸ | MMP3 | P08254 | 8/20 | 0.37 |
| ▸ | MMP9 | P14780 | 3/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7457497 | 1.00 | MMP2 (0.37) | MMP2MMP3MMP9MMP8MMP1 | |
| SCHEMBL7462650 | 1.00 | MMP2 (0.37) | MMP2MMP3MMP9MMP8MMP1 | |
| SCHEMBL7454200 | 0.92 | ADAMTS4 (0.35) | MMP1 | |
| SCHEMBL7454224 | 0.92 | ADAMTS4 (0.35) | MMP1 | |
| SCHEMBL7454216 | 0.92 | ADAMTS4 (0.35) | MMP1 | |
| SCHEMBL7607201 | 0.86 | MMP2 (0.49) | MMP2MMP3MMP9MMP8MMP1 | |
| SCHEMBL7460871 | 0.86 | KLK7 (0.36) | MMP9MMP1 | |
| SCHEMBL7445489 | 0.78 | MMP2 (0.46) | MMP2MMP3MMP9MMP1MMP14 | |
| SCHEMBL7445478 | 0.78 | MMP2 (0.46) | MMP2MMP3MMP9MMP1MMP14 | |
| SCHEMBL7445496 | 0.78 | MMP2 (0.46) | MMP2MMP3MMP9MMP1MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495699-B2 | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | AGOURON PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| US-6306892-B1 | ENZYME INHIBITORS HETEROCYCLIC AMIDES | AGOURON PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | disclosed |